Literature DB >> 11722282

Pharmacogenetics--legal, ethical and regulatory considerations.

R March1, K Cheeseman, M Doherty.   

Abstract

The overall objective of pharmacogenetics is to determine the genetic basis of variability in drug efficacy and safety, and to use this information to benefit the patient. Genetics can be used to develop drugs that are suitable for the majority of patients and to help identify those patients for whom a certain drug may not be the most appropriate. This review will cover some background to pharmacogenetics and various issues including confidentiality, data protection, coding of samples and genetic data, informed consent, and drug development guidelines. International, national and regional variation in the legal and regulatory basis for pharmacogenetics presents challenges for researchers attempting to increase scientific understanding in the field. Examples of national and international regulations and guidelines will be given. It is clear that pharmacogenetics today is a long way from the 'personalised medicine' advocated by some individuals in recent years. The aim of pharmacogenetic research should always be to make sure that patients have the best treatment available and that patients are not exposed to drugs to which they are genetically unable to respond. This vision must continue to inspire researchers and regulators who are working together to make it a widespread reality.

Entities:  

Keywords:  Biomedical and Behavioral Research; Genetics and Reproduction; Legal Approach

Mesh:

Year:  2001        PMID: 11722282     DOI: 10.1517/14622416.2.4.317

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  4 in total

1.  Racializing drug design: implications of pharmacogenomics for health disparities.

Authors:  Sandra Soo-Jin Lee
Journal:  Am J Public Health       Date:  2005-10-27       Impact factor: 9.308

Review 2.  Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations.

Authors:  Katherine I Morley; Wayne D Hall
Journal:  J Mol Med (Berl)       Date:  2003-11-04       Impact factor: 4.599

Review 3.  Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany.

Authors:  Marika Plöthner; Dana Ribbentrop; Jan-Phillipp Hartman; Martin Frank
Journal:  Adv Ther       Date:  2016-07-12       Impact factor: 3.845

4.  Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system.

Authors:  Sebastian Schleidgen; Georg Marckmann
Journal:  BMC Med Ethics       Date:  2013-05-24       Impact factor: 2.652

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.